AUTOLOGOUS ACTIVATED T-CELLS TRANSDUCED WITH A 3rd GENERATION GD-2 CHIMERIC ANTIGEN RECEPTOR AND iCASPASE9 SAFETY SWITCH ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA (GRAIN)

Trial Profile

AUTOLOGOUS ACTIVATED T-CELLS TRANSDUCED WITH A 3rd GENERATION GD-2 CHIMERIC ANTIGEN RECEPTOR AND iCASPASE9 SAFETY SWITCH ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA (GRAIN)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Anti GD2 CAR transduced T cells Bellicum Pharmaceuticals (Primary) ; Rimiducid
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Acronyms GRAIN
  • Most Recent Events

    • 26 Dec 2015 Planned End Date changed from 1 Nov 2030 to 1 Oct 2030, according to ClinicalTrials.gov record.
    • 26 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 30 Oct 2015 Planned End Date changed from 1 Aug 2030 to 1 Nov 2030 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top